SCHEMBL4353042

SCHEMBL4353042

CCNC(=O)c1ccnc(C(=O)NCC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 2/20 0.47
ITGA2B P08514 2/20 0.47
KDM5A P29375 2/20 0.47
KDM5C P41229 2/20 0.47
KDM5B Q9UGL1 2/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 1/20 0.47
KDM4E B2RXH2 3/20 0.46
KDM6B O15054 1/20 0.46
TET3 O43151 1/20 0.46
KDM4A O75164 1/20 0.46
BBOX1 O75936 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
ASPH Q12797 1/20 0.46
KDM4D Q6B0I6 1/20 0.46
TET2 Q6N021 1/20 0.46
ALKBH5 Q6P6C2 1/20 0.46
KDM7A Q6ZMT4 1/20 0.46
KDM8 Q8N371 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2713556 0.90 KDM4E (0.61) ITGB3ITGA2BKDM5AKDM5CKDM5B
SCHEMBL2714869 0.90 FTO (0.61) ITGB3ITGA2BKDM5AKDM5CKDM5B
SCHEMBL29831092 0.90 FTO (0.61) ITGB3ITGA2BKDM5AKDM5CKDM5B
SCHEMBL19439177 0.89 PARP1 (0.43) ITGB3ITGA2BKDM5AKDM5CKDM5B
SCHEMBL2716296 0.87 KDM5B (0.48) KDM5AKDM5CKDM5BKMT2AKDM4E
SCHEMBL2714272 0.87 KDM4E (0.51) KDM5AKDM5CKDM5BKMT2AMEN1
SCHEMBL29831193 0.85 SMYD3 (0.55) ITGB3ITGA2BBRD4LMNASMN1; SMN2
SCHEMBL7963734 0.84 KDM4E (0.59) KDM5AKDM5CKDM5BKDM4EKDM6B
SCHEMBL162424 0.83 PARP1 (0.45) KDM4EPARP1BRD4RIPK1LMNA
SCHEMBL8945334 0.83 POLB (0.54) ITGB3ITGA2BKDM5AKDM5CKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090280153-A1 electrical devices, anti-scarring agents, and therapeutic compositions ANGIOTECH INTERNATIONAL AG (CH) 2009-11-12 US disclosed
US-20090226500-A1 SUTURES AND ANTI-SCARRING AGENTS ANGIOTECH PHARMACEUTICALS, INC (CA) 2009-09-10 US disclosed
WO-2006121522-A2 IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS ANGIOTECH INTERNATIONAL AG (CH) 2006-11-16 WO disclosed
WO-2006121518-A2 ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS ANGIOTECH INTERNATIONAL AG (CH) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090226500-A1 SUTURES AND ANTI-SCARRING AGENTS COL1A1, COL2A1, COL14A1 ITGB3 95/4885ITGA2B 264/4885KDM5A 2074/4885
US-20090280153-A1 electrical devices, anti-scarring agents, and therapeutic compositions GAP43, TNNC1, GJB2 ITGB3 99/4885ITGA2B 147/4885KDM5A 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.